| Assistance Publique - Hopitaux De Paris Patent applications |
| Patent application number | Title | Published |
|---|
| 20120115171 | Method For Diagnosing Thrombophilia - The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S. | 05-10-2012 |
| 20120095742 | SYSTEM AND METHOD FOR PROCESSING SIGNALS FOR THE REAL-TIME DETECTION OF A FUNCTIONAL CYCLIC ACTIVITY - A system and method for processing signals for the real-time detection of a functional cyclic activity, include: elements for simultaneously receiving signals acquired by a sensor array having at least two sensors; elements for recording and preprocessing the acquired signals during a plurality of consecutive cycles; elements for identifying event combinations from the recordings of the acquired signals, enabling a calibration to be carried out, including: elements for identifying a plurality of events in the acquired signals, each signal including an identified event; elements for defining a model of the functional activity, consisting of a time order of the events and the mean delays between the events, and elements for defining a detection time window from the functional activity model. | 04-19-2012 |
| 20120095082 | USE OF INTERFERING RNA FOR TREATING AN HIV INFECTION - The present invention relates to interfering RNAs, in particular miRNAs, capable of specifically blocking the replication of a strain of the HIV virus that is resistant to an antiretroviral compound, and use thereof for treating infections by this type of virus. | 04-19-2012 |
| 20120094273 | IMMUNOLOGICAL METHOD FOR DETECTING ACTIVE JCV INFECTION - The invention relates to an immunological method for detecting an extra renal active infection by JC virus in a patient candidate for a treatment with an immunosuppressive treatment or during the course of this treatment. | 04-19-2012 |
| 20120088715 | MUTATED ANTITHROMBINS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS DRUGS - The present invention relates to the use of a composition including of at least a mutated antithrombin
| 04-12-2012 |
| 20120088257 | METHOD FOR DIAGNOSING VASCULITIS - The invention relates to a method for the in vitro detection of vasculitis or the risk of developing vasculitis, including determining the presence and/or the amount of anti-endothelial cell antibodies (AECA) or anti-vascular smooth muscle cell (VSMC) antibodies in a biological sample from a patient. | 04-12-2012 |
| 20120070855 | METHOD FOR IN VITRO ASSAY OF SOLUBLE FIBRIN BY GENERATING SPECIFIC DEGRADATION PRODUCTS - The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp. | 03-22-2012 |
| 20120066776 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 03-15-2012 |
| 20120058936 | COMPOSITIONS AND METHODS FOR ELIMINATION OF GRAM NEGATIVE BACTERIA - Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria. | 03-08-2012 |
| 20120034167 | TYROSINE KINASE RECEPTOR TYRO3 AS A THERAPEUTIC TARGET IN THE TREATMENT OF CANCER - The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer. | 02-09-2012 |
| 20120014933 | Method for Producing Platelets - The present invention relates to a method for producing platelets from mature megakaryocytes. More particularly, the invention relates to an ex vivo method for producing platelets, from mature megakaryocytes, said method comprising a step of subjecting a suspension of mature megakaryocytes to a flow having a minimal shear rate of 600 s | 01-19-2012 |
| 20110319870 | METHOD FOR INCREASING THE POOL OF NGN3+ ENDOCRINE PROGENITOR CELLS AND PANCREATIC ENDOCRINE CELL MASS - The present invention discloses a method for increasing the pool of Ngn3+ endocrine progenitor cells obtained from stem cells, by contacting said stem cells with a SUR1/Kir6.2 channel inhibitor. The invention also relates to a method for increasing the mass of pancreatic endocrine cells, in particular of β cells. The invention further concerns a method for treating diabetes. | 12-29-2011 |
| 20110301481 | SYSTEM FOR QUANTIFYING THE DISCREPANCY BETWEEN A PATIENT RECEIVING ASSISTED BREATHING AND A CORRESPONDING ASSISTANCE DEVICE - This system is characterized in that includes:
| 12-08-2011 |
| 20110269637 | Method for Predicting Clinical Outcome of Patients With Non-Small Cell Lung Carcinoma - The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient. | 11-03-2011 |
| 20110263998 | SYSTEM FOR DETECTING RESPIRATORY MUSCLE ACTIVITY OF A PATIENT RECEIVING ASSISTED BREATHING - The invention relates to a system for detecting respiratory muscle activity of a patient ( | 10-27-2011 |
| 20110229900 | METHOD FOR DETECTING MICROORGANISMS OF KINGELLA GENUS - The invention relates to a method for detecting Kingella microorganisms through PCR of a chaperonin gene. | 09-22-2011 |
| 20110183009 | Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity - The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms. | 07-28-2011 |
| 20110130830 | AORTIC RING AND ANCILLARY DEVICE FOR IMPLANTING IT - Aortic ring ( | 06-02-2011 |
| 20110129840 | METHOD, PROCESS, AND KIT FOR DIAGNOSIS OR PROGNOSIS OF COLORECTAL CANCER - A process or method and a kit for the diagnosis/prognosis and follow-up of colorectal cancer, which includes a) the extraction of nucleic material from a biological sample, b) use of at least one pair of amplification primers in order to obtain amplicons of at least one target sequence, and c) use of at least one detection probe to detect the presence of the amplicons, the process or method including a modification step between steps 1) and b). Steps b) and c) are carried out at the same time. The target sequence is included in the WIF1 gene and the pair of primers includes at least one amplification primer including at least 15 nucleotide patterns of a nucleotide sequence selected from SEQ ID nos. 1 to 10 and/or the detection probe includes at least 15 nucleotide patterns of a nucleotide sequence selected from SEQ ID nos. 1 to 10. | 06-02-2011 |
| 20110124723 | Compounds for Preventing and Treating Plasmodium Infections - The present invention relates to the use of at least one compound of formula (I) for the manufacture of a medicament intended for preventing or treating infections by a | 05-26-2011 |
| 20110086805 | IN VITRO METHOD FOR DIAGNOSING SKIN CANCER - The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene; to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell; and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer. | 04-14-2011 |
| 20110071385 | METHOD AND SYSTEM FOR LOCALIZING AN INGESTIBLE ELEMENT FOR THE FUNCTIONAL INVESTIGATION OF THE DIGESTIVE TRACT - A non-invasive exploration method for assessing the digestive motility of a subject including the subject swallowing an ingestible transmitting element containing a transmission means transmitting at a given fixed frequency, measuring in series the phase-shift of the frequency transmitted by each of at least three transportable reception means relative to a reference phase of a reference beacon to fix the origin of a coordinates system and the coordinates of each transportable reception means. Each of the reception means including a transceiver where the reception means is distributed around the subject and the reference beacon is attached to a given fixed location on the subject. The method includes measuring the phase shift of the frequency transmitted by the transmission means of the ingestible element to obtain at least three phase-shift measurements and determining by triangulation based on the phase-shift measurements a position of the ingestible element in the coordinates system. | 03-24-2011 |
| 20110059184 | MEDICAMENT FOR TREATING PARKINSON'S DISEASE - The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, bee's venom is used in an amount of between 33 and 330 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy. | 03-10-2011 |
| 20110044906 | Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer - The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer. | 02-24-2011 |
| 20110014691 | METHOD FOR GENERATING PRIMATE CARDIOVASCULAR PROGENITOR CELLS FOR CLINICAL USE FROM PRIMATE EMBRYONIC STEM CELLS OR EMBRYONIC-LIKE STATE CELLS, AND THEIR APPLICATIONS - The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention. | 01-20-2011 |
| 20110009330 | MEDICAMENT FOR TREATING PARKINSON'S DISEASE - The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, apamine is used in an amount of between 1 and 10 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy. | 01-13-2011 |
| 20100215629 | TREATMENT OF TUMORS USING T LYMPHOCYTE PREPARATIONS - The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment. | 08-26-2010 |
| 20100209903 | Method for measuring resistance of a patient HIV-2 to protease inhibitors - A search method in a biological sample containing an HIV-2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV-2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient. | 08-19-2010 |
| 20100196417 | COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition. | 08-05-2010 |
| 20100183555 | METHODS AND KITS FOR DETERMINING DRUG SENSITIVITY IN PATIENTS INFECTED WITH HCV - An in vitro method for determining whether a patient infected with HCV is a responder or non-responder to the treatment with interferon-alpha and ribavirin. More specifically, the method includes a step of determining the expression level of the IFI27, CXCL9 and G1P2 genes in a biological sample. | 07-22-2010 |
| 20100167273 | Method for Selectively Quantifying Vegf Isoforms in a Biological Sample and Uses Thereof - The present invention pertains to a novel method for quantifying VEGF various isoforms in a biological sample, with a very high selectivity and sensitivity. It also concerns a method for establishing a diagnostic and/or a prognosis concerning a patient potentially suffering from cancer, diabetes, or cardiovascular disease, comprising a step of determining the level of at least one of the VEGF isoforms, in a biological sample from said patient. | 07-01-2010 |
| 20100166737 | P38Alpha as a Therapeutic Target in Bladder Carcinoma - The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors. | 07-01-2010 |
| 20100145728 | INTEROPERABILITY PLATFORM - The present application relates to a computer system for processing customized medical records comprising dedicated equipment for the acquisition of specialized information, as well as, for each healthcare facility, of aggregation equipment for the centralization of the information in view of delivering a customized medical record formed from information coming from said dedicated equipment, and for the distribution of the customized medical records to various operators acting on behalf of at least one healthcare network, characterized in that it comprises an interoperability platform having computer connectors configured for the exchanges between said interoperability platform and each of the aggregation equipment of said healthcare facilities, and computer connectors configures for the exchanges between said interoperability platform and each of said operators, wherein said platform comprises means for conditional routing to one of said operators depending on the information registered in relation to the digital file corresponding to the customized medical record and means for transcoding said file according to the nominal format of said target operator. | 06-10-2010 |
| 20100143894 | Quantitative Detection of Hdv by Real-Time Rt-Pcr - Specific reagents for quantitative assay of HDV and more specifically to follow HDV viral load in chronically infected patients and such a quantitative assay. | 06-10-2010 |
| 20100131286 | METHODS FOR THE PROGNOSIS OR FOR THE DIAGNOSIS OF A THYROID DISEASE - The present invention relates to methods for predicting or diagnosing a thyroid disease in an individual. | 05-27-2010 |
| 20100094406 | ENDOPROSTHESIS, AND METHOD FOR PRODUCING AN ENDOPROSTHESIS - The endoprosthesis is designed to be implanted in an aneurysm ( | 04-15-2010 |
| 20100093863 | USE OF CITRULLINE FOR PREVENTING AN INCREASE IN PROTEIN CARBONYLATION AND FOR TREATING DISEASES RESULTING THEREFROM - A method of using L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonylation, in particular for treating neurodegenerative diseases such as Alzheimer's or Parkinson's disease. | 04-15-2010 |
| 20100015219 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULT TO IMPROPERLY DIVERT FROM THEIR INTENDED ROUTE OF ADMINISTRATION - A solid pharmaceutical composition in the form of a gel capsule containing at least one active ingredient and also at least one gelling agent chosen from cellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylmethylcellulose, sodium carboxymethylcellulose (CMC) and calcium carboxymethylcellulose, and at least one disintegrating agent, the gelling agent and the disintegrating agent being present in a ratio by weight of 0.3 to 0.7/1 and the content by weight of gelling agent(s) being from 10% to 20% of the composition, and method for preparing same. | 01-21-2010 |
| 20090325194 | USE OF SPLA2 ACTIVITY FOR THE DIAGNOSIS OF A CARDIOVASCULAR EVENT - A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed. | 12-31-2009 |
| 20090306212 | Compositions and Methods for Treating Diabetes and Neuropsychological Dysfunction - The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders. | 12-10-2009 |
| 20090298713 | POLYNUCLEOTIDES WHICH ARE OF NATURE B2/D+ A- AND WHICH ARE ISOLATED FROM E. COLI, AND BIOLOGICAL USES OF THESE POLYNUCLEOTIDES AND OF THEIR POLYPEPTIDES - The present invention relates to products which are of nature B2+ A−, isolated from | 12-03-2009 |
| 20090269310 | METHOD FOR OBTAINING HUMAN SMOOTH MUSCULAR CELLS AND USES THEREOF - The invention concerns a method for obtaining in vitro a population of cells comprising essentially human smooth muscular cells expressing calponin and SM-MHC from a sample of human muscular biopsy or from human muscular biopsies differentiated in vitro into skeletal muscle cells. The invention also concerns a composition comprising the isolated smooth muscular cells obtainable by said method as therapeutic principle designed for humans. The invention further concerns the use of the isolated smooth muscular cells for preparing a therapeutic composition designed to replace smooth muscular cells. In particular, the invention concerns the use of said isolated smooth muscular cells for treating ischemia, cancer or any disease requiring revascularization of damaged tissues. Finally, the invention concerns the use of said smooth muscular cells as vector for an active principle for preparing a therapeutic composition designed for humans requiring treatment with said active principle. | 10-29-2009 |
| 20090253122 | Method for measuring resistance of a patient HIV-2 to protease inhibitors - A search method in a biological sample containing an HIV 2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV 2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient. | 10-08-2009 |
| 20090202992 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 08-13-2009 |
| 20090136533 | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41. | 05-28-2009 |
| 20090117554 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a method and a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 05-07-2009 |
| 20090117110 | Method for the In Vitro Assessment of the Progression Status of an Infection by an HIV Virus in an Individual - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. | 05-07-2009 |
| 20090028875 | USE OF GILZ PROTEIN EXPRESSED IN DENDRITIC CELLS TO MODULATE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections. | 01-29-2009 |
| 20080261212 | Method of Diagnosis/Prognosis of Human Chronic Lymphocytic Leukemia Comprising the Profiling of Lpl/Adam Genes - The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a patient in need thereof and methods to determine IgVH mutational status. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL. | 10-23-2008 |
| 20080200817 | Electronic Polarimetric Imaging System for a Colposcopy Device and an Adapter Housing - The invention relates to an electronic polarimetric imaging system use in a colposcopy device for in vivo monitoring a cervix, which is provided with a light source for illuminating the observable cervix and at least visual means for monitoring said cervix, wherein the illumination optical path directed to the cervix and the image optical path coming back from the cervix are separated from each other on at least a portion of the paths thereof. The inventive system comprises a polarimetric adapter housing which is removable in the separated portion of the illumination and image optical paths and comprises a polarization state generator (PSG) positioned on the illumination optical path and a polarization analyser (PSA) positioned on the image optical path, wherein said polarization state generator (PSG) and polarization analyser (PSA) are designed in such a way that they are controllable. Said invention makes it possible to obtain several polarimetric characterisation levels. The adapter housing is also disclosed. | 08-21-2008 |
| 20080199397 | Use of a Tetrapeptide Acsdkp Analogue Resistant to the Angiotensin i Conversion Enzyme, for Measuring Glomerular Filtration Rate in a Human or an Animal and Kit Containing Same - The invention concerns the use of ACE-resistant N-acetyl-Ser-Asp-Lys-Pro analogues for preparing a reagent or marker adapted to measure a glomerular filtration rate. | 08-21-2008 |
